Vimian Q2 2026: Innovation Pivot and Dental Margin Inflection

Double-digit organic growth, a new Specialty Pharma R&D focus, and M&A momentum mark a strategic shift for the animal health company.

VIMIAN.ST · Earnings Call · 2026-07-17

The Quarter in Numbers

Vimian Group delivered a strong Q2 2026, with revenue up 17% to EUR 121.6 million and organic growth of 12%. Adjusted EBITA grew 17% to EUR 29.7 million, with margin expanding to 24.5%. The company highlighted strong business momentum across all four segments, with double-digit organic growth in Specialty Pharma, MedTech, and Veterinary Services.

MedTech's Dental Margin Story and the U.S. Turnaround

The MedTech segment returned to double-digit growth (11%), with the U.S. Orthopedic business returning to growth after a challenging period. As CEO Alireza Tajbakhsh noted, “we expect that the changes we've implemented to drive kind of continued growth in the U.S. Orthopedic business will continue” — Alireza Tajbakhsh, Group CEO · 2026-07-17. The Dental segment, however, is where margins are inflecting. The consolidation of the AllAccem acquisition, completed in June last year, is a key driver. CFO Carl-Johan Zetterberg Boudrie said, “we do see that margins will improve over time, also in the Dental area within MedTech” — Carl-Johan Zetterberg Boudrie, CFO and interim Head of Specialty Pharma · 2026-07-17. This is a significant shift from the previous year, when the company was still in the early stages of its turnaround. In the February 2026 call, the CEO noted, “We see early operational improvements, but we are undergoing significant change with the new sales team fully in place as of January” — Alireza Tajbakhsh, Group CEO · 2026-02-12. The current quarter suggests that change is now translating into results.

Specialty Pharma: Innovation as the New Growth Engine

Perhaps the most notable shift in Vimian's narrative is the emphasis on innovation within Specialty Pharma. The CFO, who is currently interim head of the segment, highlighted that innovation is at the core of its strategy.

Innovation is really at the heart of Specialty Pharma's growth strategy.
Carl-Johan Zetterberg Boudrie, CFO and interim Head of Specialty Pharma · 2026-07-17

The company launched 75 new products over the last 12 months, with more than 60 in the pipeline. The establishment of a new R&D hub in France focused on biological pharmaceuticals underscores this commitment. Meanwhile, a successful national sales program in Specialized Nutrition contributed to the 14% organic growth in the segment, though the CFO cautioned that the program creates variability between quarters. This innovation push is a departure from the company's earlier focus on cross-selling as a primary organic growth driver. In the prior quarter, the company attributed a third of its organic growth to cross-selling initiatives, but now the conversation has shifted toward innovation and product development. In the October 2025 call, Magnus Kjellberg highlighted the strong momentum: “Organic growth in Specialty Pharma. So we had organic growth in all 4 therapeutic areas in the quarter with particularly strong growth in Specialty Pharmaceuticals and Specialised Nutrition” — Magnus Kjellberg, Head of Specialty Pharma · 2025-10-22. That growth is now being reinforced by a steady pipeline of differentiated products.

M&A Momentum and Capital Flexibility

Vimian has also accelerated its M&A activity, closing four acquisitions year-to-date. The CEO expressed confidence in the pipeline: “We feel positive about the opportunities of welcoming new strong businesses and entrepreneurs during the second half-year” — Alireza Tajbakhsh, Group CEO · 2026-07-17. Leverage is stable at 2.1x, providing dry powder for further deals. This continues the momentum noted in the February call, where the CEO said, “We see an increased M&A momentum” — Alireza Tajbakhsh, Group CEO · 2026-02-12. The company's ability to execute on M&A while improving organic growth is a key differentiator.

The Bigger Picture

Vimian is executing well on multiple fronts: organic growth is above the global animal health market, margins are expanding, and the innovation engine is firing. The innovation strategy in Specialty Pharma adds a new growth dimension, while the Dental margin improvement demonstrates operational leverage. The consolidation of acquired businesses is now clearly benefiting margins. With a strong M&A pipeline and a solid balance sheet, the company is well-positioned for the second half.